How AI is Revolutionising the Fight Against Cancer and Diabetes

• AI is accelerating medical research by identifying drug targets, predicting disease risk, and designing personalized therapies for cancer and Type 1 diabetes (T1D).
• While cancer stems from an underactive immune system and T1D from an overactive one, both represent immune system imbalances targeted by AI-driven analysis.

Advancing Cancer Immunotherapy

• Drug Discovery: Machine learning models analyze massive datasets, including genetic sequences and single-cell profiles, to identify novel tumor antigens and immune checkpoint molecules that help tumors escape detection.
• Biomarker Discovery: AI deep learning models integrate medical imaging, genomic sequencing, and immune signatures to predict patient responses to checkpoint inhibitors, improving clinical trial precision.
• Treatment Optimization: AI analyzes proteomics and genomics to predict tumor behavior (classifying "hot" vs. "cold" tumors), helping doctors tailor combinations of therapies to reduce toxicity.
• Personalized Vaccines: AI predicts which neoantigens trigger the strongest immune response, accelerating the creation of personalized cancer vaccines that have shown success in early liver and kidney cancer trials.

Transforming Type 1 Diabetes Care

• Early Detection: Machine learning models using data from cohorts like TEDDY combine genetic risk, immune markers, and metabolic data to predict T1D onset in children as early as age six.
• Cellular Insight: Advanced AI analysis has identified new populations of CD4+ T cells responsible for attacking pancreatic β-cells, providing clarity that traditional methods missed.
• Automated Management: "Artificial pancreas" systems use AI to process real-time continuous glucose monitoring (CGM) data, dynamically adjusting insulin delivery to maintain target glucose levels more consistently than standard pumps.